Gabon
Tuberculosis profile
| High HIV burden |
Population  2013 1.7 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.91 (0.54–1.3) 55 (32–78)
Mortality (HIV+TB only) 0.18 (0.14–0.23) 11 (8.3–14)
Prevalence  (includes HIV+TB) 9.7 (4.9–16) 578 (294–954)
Incidence  (includes HIV+TB) 7.1 (6.3–8) 423 (378–476)
Incidence (HIV+TB only) 0.79 (0.7–0.89) 47 (42–53)
Case detection, all forms (%) 73 (65–82)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
100 (0–220) 110 (2–240)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 930   469
Pulmonary, clinically diagnosed 2 099   152
Extrapulmonary 529   0
       
Total new and relapse 5 179    
Previously treated, excluding relapses 246    
Total cases notified 5 425    
Among 1 930 new cases:
72 (4%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     8
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 425 (100)
HIV-positive TB patients 605 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 442 (73)
HIV-positive TB patients on antiretroviral therapy (ART) 442 (73)
HIV-positive people screened for TB 547  
HIV-positive people provided with IPT 11  
Treatment success rate (%)
New and relapse cases registered in 2012 54
Previously treated cases, excluding relapse, registered in 2012 18
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 3.0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 5.1
% Funded domestically 21%
% Funded internationally <1%
% Unfunded 78%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-27 Data: www.who.int/tb/data